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Activated protein C (APC) is a natural anticoagulant and inhibitor of inﬂammation that can stimulate keratinocyte
wound repair in vitro and promote wound healing in vivo. The signaling mechanisms, however, are unknown and a
keratinocyte receptor for APC has not been identiﬁed. Here, we show that cultured human keratinocytes from
neonatal foreskins express the endothelial protein C receptor (EPCR). EPCR was also strongly expressed by lower
epidermal layers of neonatal foreskin as determined by immunohistochemistry. In cultured keratinocytes, EPCR
expression was upregulated by the addition of APC and inhibited by tumor necrosis factor-a. Addition of APC
stimulated cell proliferation, production of matrix metalloproteinase-2, activation of ERK and p38 kinase signaling
pathways, and expression of protease-activated receptor (PAR)-1. A monoclonal antibody, RCR252, which blocks
APC binding to EPCR, or a blocking antibody to PAR-1, abolished APC’s effects on keratinocytes. In summary, this
study demonstrates that EPCR, a major receptor of protein C pathway, is expressed by human keratinocytes, and
facilitates APC’s function on keratinocytes via activation of PAR-1 pathway. Our ﬁndings highlight a possible new
role for the protein C pathway in skin physiology and help elucidate the mechanisms of action by which APC
promotes wound healing.
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Protein C, a vitamin K-dependent zymogen, is converted
into activated protein C (APC) on the endothelial surface
when thrombin binds to thrombomodulin. The activation of
PC is augmented by the endothelial protein C receptor
(EPCR) (Fukudome et al, 1998; Xu et al, 1999), which con-
centrates protein C on the endothelial cell surface, reducing
the Km for PC activation by the thrombin–thrombomodulin
complex. APC plays a key role in the regulation of blood
coagulation and also has significant anti-inflammatory prop-
erties associated with decreases in pro-inflammatory
cytokines and a reduction of leukocyte recruitment (Mu-
rakami et al, 1997; Yuksel et al, 2002). The effectiveness of
APC as an anti-inflammatory agent is demonstrated by
its efficacy as a treatment for patients with severe sepsis
(Griffin et al, 2002).
Many of the anti-inflammatory properties of APC are
mediated through EPCR, which itself is anti-inflammatory
(Esmon, 2004). EPCR is a 46-kDa type I transmembrane
glycoprotein homologous to major histocompatibility com-
plex class I/CD1 family proteins (Fukudome and Esmon,
1994; Villoutreix et al, 1999). EPCR is predominantly ex-
pressed by endothelial cells, mainly of larger blood vessels
(Laszik et al, 1997), although recent reports have shown it to
be present on some leukocytes of the innate immune sys-
tem (Galligan et al, 2001; Feistritzer et al, 2003; Sturn et al,
2003). APC also promotes the activation of protease-acti-
vated receptors (PAR) (Riewald et al, 2002, 2003), in
particular PAR-1, in an EPCR-dependent manner that con-
tributes to the anti-inflammatory actions of APC (Riewald
et al, 2002, 2003; Domotor et al, 2003; Guo et al, 2004). In a
model of focal ischemic stroke in mice, the reduction of
brain infarction by APC is attenuated in EPCR-deficient
mice, and the neuroprotective role of APC is abolished by
PAR-1 blocking antibodies (Domotor et al, 2003).
Keratinocytes, a major cell type of human skin, exist at
various stages of differentiation corresponding to different
epidermal layers (Bikle et al, 2001). When the skin is injured,
keratinocytes ‘‘re-epithelialize’’ by proliferating and migrat-
ing in response to various mediators including cytokines,
chemokines, and matrix metalloproteinases (MMP) (Lavker
and Matoltsy, 1971; Garlick and Taichman, 1994). MMP play
an important part in wound healing by modulating the ex-
tracellular matrix for cell integrity, viability, proliferation, and
mobility. MMP-2 is unique among the MMP in that it is
constitutively expressed and its propeptide sequence is not
susceptible to proteolytic activation by endopeptidases
Abbreviations: APC, activated protein C; EPCR, endothelial cell
protein C receptor; MAPK, mitogen-activated protein kinase; MMP,
matrix metalloproteinase; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide; PAR, protease-activated receptor;
RT, reverse transcription; TNF, tumor necrosis factor
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such as trypsin, plasmin, or thrombin (Okada et al, 1990).
MMP-2 is a versatile proteinase capable of cleaving several
collagen types (Aimes and Quigley, 1995; Kahari and Sa-
arialho-Kere, 1997), activating other MMP (Cowell et al,
1998), and cleaving inflammatory mediators (McQuibban
et al, 2000). The vital role that MMP-2 plays during wound
healing is reflected by its specific requirement for epithelial
growth and migration both in vitro and in vivo (Makela et al,
1999).
Recently, a novel function of APC as a promoter of cu-
taneous wound healing was identified. In a rat healing
model, APC accelerated full-thickness wound closure by
stimulating re-epithelialization, promoting angiogenesis,
and preventing inflammation (Jackson et al, 2005). In cul-
tured human keratinocytes, APC enhanced cell prolifera-
tion, migration, and MMP-2 activity (Xue et al, 2004). The
signaling mechanism(s) by which APC performs these func-
tions, however, is unknown, and a keratinocyte receptor for
APC has not been identified.
This study shows that the major PC/APC receptor,
EPCR, is highly expressed by human keratinocytes and is
required for their increased proliferation and MMP-2 activity
in response to APC. In addition, this pathway involves ac-
tivation of PAR-1 and mitogen-activated protein kinase
(MAPK).
Results
EPCR is expressed by human keratinocytes To deter-
mine whether human keratinocytes express EPCR, primary
cultures of keratinocytes were maintained in keratinocyte
serum-free medium for 24 h, followed by assessment of
EPCR expression using RT-PCR, immunoblotting, and
immunohistochemistry. EPCR mRNA was expressed by
keratinocytes as shown by the prominent band at 450 bp
(Fig 1A). In concert with gene expression, EPCR protein was
detected in the cell lysates of unstimulated keratinocytes by
immunoblotting (Fig 1B). There was no detectable EPCR
protein in the cell culture supernatants (Fig 1B), indicating
that the receptor is not shed from the cell surface under
these experimental conditions. Cultured human keratin-
ocyte monolayers stained strongly positive for EPCR using
immunohistochemistry, confirming that the receptor is high-
ly expressed by these cells (Fig 1C).
EPCR expression was also assessed in neonatal foreskin
tissue using immunohistochemistry. The receptor was strong-
ly expressed in the epidermis, an avascular tissue with the
major cellular component being multiple layers of keratin-
ocytes ranging from the lower basal layer comprising prolif-
erating cells to the upper horny layer (stratum corneum),
where the cells are non-viable. EPCR expression was most
prominent in the basal and suprabasal layers of the epider-
mis, and decreased toward the outer stratum corneum, where
the keratinocytes lose their viability (Fig 1D). As described
previously (Laszik et al, 1997), EPCR was also immunolocal-
ized to dermal vascular endothelial cells and cells within the
blood vessels, presumably leukocytes (Fig 1D).
APC upregulates EPCR and PAR-1 in human keratin-
ocytes The expression of EPCR and PAR-1 by keratinocytes
following treatment with APC was examined by RT-PCR and
western blot analysis. APC upregulated EPCR gene (Fig 2A)
and protein (Fig 2B) expression, which peaked at 10 ng per
mL APC treatment (Fig 2A,B). The gene and protein ex-
pression of PAR-1 in response to APC was also upregulated
in a dose-responsive manner, with a peak response at 1 mg
per mL APC (Fig 2C,D). In contrast to APC, treatment with
tumor necrosis factor-a (TNF-a) concentration dependently
(1–100 ng per mL) downregulated both mRNA and protein
expression of EPCR in keratinocytes (Fig 2E,F). When used
at 100 ng per mL, TNF-a reduced EPCR protein expression
by approximately 85%.
APC activates ERK2 and p38 in keratinocytes Under
basal conditions, cultured keratinocytes expressed the ac-
tive (phosphorylated) forms of both ERK2 and p38. Treat-
ment with APC (0.01–20 mg per mL) for 24 h concentration
dependently stimulated the expression of these phosphory-
lated MAPK metabolites (Fig 3A). The addition of EPCR
blocking antibody, RCR252, resulted in a concentration-
dependent decrease of the APC-stimulated phosphorylated
form of ERK2 and p38 (Fig 3B). These results suggest that
activation of ERK2 and p38 by APC is mediated through
EPCR.
Figure1
Endothelial protein C receptor (EPCR) expression in cultured hu-
man keratinocytes and neonatal foreskin. Cells were seeded on
slides and incubated for 24 h and EPCR was detected by (A) RT-PCR
(left lane—markers; right lane—EPCR 450 bp), (B) western blot analysis
using culture supernatants and cell lysates, and (C) immunohistochem-
ical staining for EPCR in keratinocytes (scale bar¼40 mm), as de-
scribed in Materials and Methods. (D) Neonatal foreskin sections were
processed using immunohistochemistry for expression of EPCR. The
sub-epidermal layers (arrowheads) and dermal vessels (arrows) stained
positive for EPCR (scale bar¼ 100 mm).
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APC-stimulated cell proliferation is EPCR and PAR-1
dependent As shown in Fig 4A, APC stimulated the pro-
liferation of keratinocytes (Xue et al, 2004). To test whether
this stimulation was dependent on APC binding to EPCR
and/or cleavage of PAR-1, keratinocytes were pre-treated
with RCR252 (0.1–10 mg per mL), RCR92 (10 mg per mL), or
anti-PAR-1 blocking antibody (0.1–10 mg per mL), followed
by the addition of APC (10 mg per mL) for 72 h. Proliferation
of APC-treated cells was concentration dependently inhib-
ited by treatment with RCR252, whereas RCR92 had no
effect (Fig 4B). Anti-PAR-1 blocking antibody also concen-
tration dependently inhibited APC-induced proliferation (Fig
4C). When used at 10 mg per mL, anti-PAR-1 inhibited pro-
liferation by up to 60%.
Stimulation of MMP-2 by APC is EPCR and PAR-1 de-
pendent Keratinocyte production of MMP-2 and MMP-9
was examined using zymography and ELISA. APC (0.1–20
mg per mL) concentration dependently upregulated the ex-
pression and activation of MMP-2 in cultured keratinocytes
but had no effect on MMP-9 levels (Fig 5A). Blocking EPCR
by RCR252 inhibited APC-induced MMP-2 production. At
10 mg per mL, RCR252 reduced MMP-2 production by
 40% (Fig 5B,C). The blocking PAR-1 antibody (0.1–10 mg
per mL) also concentration dependently inhibited APC-in-
duced MMP-2 production (Fig 6A,B) and MMP-9 to a lesser
extent (Fig 6A). Overall, these data indicate that APC acts
through EPCR and PAR-1 to induce MMP-2 production.
Figure 2
Activated protein C (APC) and tumor necrosis factor-a (TNF-a)
regulate endothelial protein C receptor (EPCR) and protease-ac-
tivated receptor (PAR)-1 expression in keratinocytes. Cells were
stimulated with APC (0–10 mg per mL) or TNF-a (0–100 ng per mL) for
24 h. Total RNA was extracted for RT-PCR, and whole-cell lysates were
obtained for western blot analysis. Agarose gels and western blots
show (A) gene and (B) protein expression of EPCR in response to APC
treatment; (C) gene and (D) protein expression of PAR-1 in response to
APC treatment; and (E) gene and (F) protein expression EPCR in re-
sponse to TNF-a treatment. b-actin was used as an internal standard.
Images represent one of three independent experiments. Western
blotting results were semi-quantified by imaging analysis software. Im-
ages represent one of three independent experiments. Data are ex-
pressed as mean  SD and represent one of three independent
experiments. po0.05, po0.01.
Figure3
Activation of ERK2 and p38 in keratinocytes in response to acti-
vated protein C (APC) and endothelial protein C receptor antibody.
Keratinocytes were treated with 0–10 mg per mL APC or 0–10 mg per mL
RCR252 15 min prior to addition of 10 mg per mL APC. After 24 h,
phosphorylated forms of ERK2 and p38 were detected in the whole-cell
lysates using western blot and semi-quantified by imaging analysis
software. Images represent one of three independent experiments.
Data are expressed as mean  SD, and represent one of three inde-
pendent experiments. In comparison with control; þ in comparison
with APC treatment. þ or po0.05, þ þ or po0.01.
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Discussion
EPCR was first identified on endothelial cells, mainly on
larger blood vessels (Laszik et al, 1997). In addition to being
involved in the activation of PC, EPCR has significant anti-
inflammatory properties (Taylor et al, 2000; Esmon, 2004).
For example, severe EPCR deficiency adversely affects the
survival and cardiac function of mice subjected to challenge
by endotoxin infusion (Iwaki et al, 2005). Baboons treated
with an antibody to block PC binding to EPCR respond
lethally to normally sublethal concentrations of Escherichia
coli and exhibit disseminated intravascular coagulation,
intense neutrophil influx into the tissues, and elevation of
inflammatory cytokines, indicating that EPCR provides a
critical step in the host defense against E. coli (Taylor et al,
2000). In keratinocytes, that EPCR expression was down-
regulated by TNF-a and upregulated by APC (Fig 2) is
consistent with its anti-inflammatory effects and its aug-
mentation of APC function (Riewald et al, 2002, 2003; Do-
motor et al, 2003; Guo et al, 2004). These results are also in
Figure 4
Blocking endothelial protein C receptor (EPCR) or protease-acti-
vated receptor (PAR)-1 inhibits activated protein C (APC)-induced
proliferation of keratinocytes. Keratinocytes were treated with (A)
0–10 mg per mL APC, (B) 0–10 mg per mL RCR252 (EPCR blocking
antibody) or 10 mg per mL RCR92 (EPCR non-blocking antibody), or (C)
0–10 mg per mL anti-PAR-1 blocking antibody (PAR-1 Ab) for 15 min
followed by 1 mg per mL APC. After 3 d, proliferation was measured by
the MTTassay. Data are expressed as mean  SD and represent one of
three independent experiments. po0.05, po0.01 (MTT, 3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide).
Figure5
Matrix metalloproteinases (MMP)-2 and MMP-9 secretion by ker-
atinocytes in response to activated protein C (APC) and endothelial
protein C receptor antibody. (A) Keratinocytes were treated with 0–20
mg per mL APC for 24 h and culture supernatants were assayed for
MMP by zymography. (B, C) Keratinocytes were treated with 0–10 mg
per mL RCR252 for 15 min followed by 10 mg per mL APC. After 24 h,
culture supernatants were assayed for MMP-2 using (B) zymography
and (C) ELISA with data expressed as mean  SEM (n¼ 3). po0.05,
po0.01.
Figure6
Matrix metalloproteinases (MMP)-2 and MMP-9 secretion by ker-
atinocytes in response to activated protein C (APC) and protease-
activated receptor (PAR)-1 antibody. Keratinocytes were treated with
0–10 mg per mL anti-PAR-1 blocking antibody (PAR-1 Ab) for 15 min
followed by 10 mg per mL APC. After 24 h, culture supernatants were
assayed for MMP-2 using (A) zymography and (B) ELISA with data
expressed as mean  SEM (n¼ 3). po0.05, po0.01.
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agreement with a previous study using monocytes (Fuku-
dome and Esmon, 1994).
In addition to EPCR’s anti-inflammatory effects, its crystal
structure has recently revealed a potential new role in reg-
ulating the immune response (Oganesyan et al, 2002). EPCR
is structurally similar to the CD1/MHC class I family of mol-
ecules and can bind a ligand in the lipid-containing antigen-
presenting groove. The CD1 family members play direct roles
in presenting lipid antigens to T cells and host defense
against certain bacterial pathogens (Hong et al, 1999; Moody
et al, 1999; Esmon, 2004). In addition to endothelial expres-
sion, EPCR appears be restricted to cells of the innate im-
mune system (Joyce et al, 2004) as it is found in resting
human neutrophils, monocytes, eosinophils, and natural killer
cells (CD56 positive) but not T cells (CD3, CD4, or CD8 pos-
itive) or B cells (Galligan et al, 2001; Feistritzer et al, 2003;
Sturn et al, 2003; Joyce et al, 2004). This finding that EPCR is
strongly expressed by skin keratinocytes raises the possibil-
ity that this receptor may be involved in the innate immune
host defense of human skin after insult or injury.
Strong evidence is now emerging that the PC pathway
contributes to wound repair. Uchiba et al (2004) have shown
that APC acts through EPCR to stimulate proliferation and
tube formation of cultured endothelial cells and promote an-
giogenesis in the rabbit corneal assay. In a rat healing model,
APC induces angiogenesis and re-epithelialization while in-
hibiting inflammation to promote cutaneous wound healing
(Jackson et al, 2005). APC also stimulates proliferation, mi-
gration, MMP-2 production, and prevents apoptosis in hu-
man skin keratinocytes (Xue et al, 2004). This study shows
that two of the vital processes of re-epithelialization, prolif-
eration and MMP-2 production (Xue et al, 2004), are signif-
icantly inhibited by blocking APC binding to EPCR. These
data provide strong evidence that APC acts through EPCR to
promote re-epithelialization in human keratinocytes and
highlight the importance of EPCR during wound healing.
APC-induced keratinocyte proliferation and MMP-2 pro-
duction was diminished by blocking PAR-1 (Figs 4 and 6).
Although PAR-1 is recognized as a thrombin receptor, Ri-
ewald et al (2002, 2003) have shown that by utilizing EPCR
as a co-receptor, APC can cleave PAR-1 on the endothelial
surface and upregulate the production of monocyte chemo-
attractant protein-1. Interestingly, PAR-1 cleavage by
thrombin induces inflammation (Coughlin, 1999; Vergnolle
et al, 2001; Coughlin and Camerer, 2003), whereas its
cleavage by APC appears to promote anti-apoptotic and
neuroprotective effects (Domotor et al, 2003; Marshall,
2003). Thus, by signaling through the same PAR-1 receptor,
APC and thrombin can exert distinct biological effects in
endothelial cells. It has been proposed that APC’s ability to
reduce mortality in sepsis is due in part to EPCR-bound
APC proteolysis of PAR-1 on the surface of endothelial cells
(Domotor et al, 2003; Riewald et al, 2003; Riewald and Ruf,
2005). Ludeman et al (2005), however, have recently raised
doubt as to whether PAR-1 cleavage by APC is physiolog-
ically important in endothelial cells. They showed that the
concentration of APC required for PAR-1 cleavage is 103 to
104 times higher than that for thrombin and substantially
higher than the plasma concentration of APC found in vivo,
and suggested that endogenous APC is unlikely to contrib-
ute to PAR-1 cleavage in vivo, at least in endothelial cells.
Nonetheless, APC–EPCR cleavage of PAR-1 may be phys-
iologically relevant in skin keratinocytes. The effectiveness
of this pathway may depend on the co-ordinate expression
and concentration of EPCR and PAR-1 (Ludeman et al,
2005), both of which are constitutively expressed in rela-
tively high levels in cultured keratinocytes (Algermissen
et al, 2000) (Fig 1). Although PAR-1 is generally more re-
sponsive to APC at higher concentrations than EPCR, the
levels of both receptors were significantly elevated by 10 ng
per mL APC (Fig 2), which is likely to be physiologically
relevant, especially in wounded skin where blood leakage
and thrombin activation of protein C occur. The exact con-
tribution of PAR-1 during APC-induced re-epithelialization
needs further investigation.
The MAPK pathway is a prerequisite for growth factor-
stimulated mitogenesis in many cell types (Roux and Blenis,
2004). Three major downstream MAPK cascades are mito-
gen-activated ERK1/2 and stress/cytokine-activated p38
and c-Jun N-terminal kinases. In this study, APC activated
p38 and ERK2 in human keratinocytes, and the addition of
blocking EPCR antibody prevented this activation, showing
that APC activates the MAPK pathway via EPCR. These
results are in accord with a recent study on endothelial cells,
which found that APC induces cell proliferation via activa-
tion of the ERK1/2 pathway (Uchiba et al, 2004). The latter
study, however, demonstrated that phosphorylated ERK1/2
and MEK1/2 levels were elevated for only  15 min after
APC stimulation and rapidly dropped back to control levels,
whereas this study showed that APC sustained the activa-
tion of p38 and ERK2 for 24 h. Recent reports explain how
ERK kinetics cause differential activation and cellular re-
sponses (Murphy et al, 2002). Transient ERK activation de-
pends on rapid increases of growth factors but not on their
final concentrations, whereas sustained ERK activation de-
pends on the final concentration (Sasagawa et al, 2005).
The Ras and Rap1 systems capture the temporal rate and
concentration of growth factors, and encode these distinct
physical properties into transient and sustained ERK acti-
vation, respectively (Sasagawa et al, 2005). Furthermore,
transient activation of ERK induces the expression of Fos by
phosphorylating the Elk and Sap transcription factors (Mur-
phy et al, 2002). As the Fos protein is very unstable, the
impact on a transcriptional response is limited. In contrast,
sustained ERK signaling results in the activation of Rsk,
which phosphorylates and stabilizes Fos, producing a ro-
bust transcriptional activation.
In summary, we have demonstrated that the major re-
ceptor of the PC pathway, EPCR, is strongly expressed by
human skin keratinocytes. Furthermore, our data suggest
that keratinocyte proliferation and induction of MMP-2 by
APC may act through EPCR, PAR-1, and MAP kinase ac-
tivity. These findings highlight the potential importance of
the PC pathway in skin physiology and help elucidate the
mechanisms of action by which APC promotes wound
healing.
Materials and Methods
Culture and experimental treatment of keratinocytes Normal
keratinocytes were isolated from neonatal foreskins (n¼ 30) in ac-
cordance with ethics approval by the ethical committee of Royal
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North Shore Hospital. Briefly, each foreskin was digested with
0.1% Trypsin in phosphate-buffered saline (PBS) at 41C overnight.
The epidermal layer was then separated from the dermis and
transferred to fresh PBS with 0.01% Trypsin. Keratinocytes were
dispersed by pipetting up and down, and the trypsin was inacti-
vated by fetal calf serum. Extracted cells were cultured using ker-
atinocyte-serum free medium (K-SFM, Gibco, Invitrogen Corp.,
Lakewood, New Jersey) supplemented with gentamycin (5 mg per
mL) plus epidermal growth factor (EGF) (5 ng per mL) and bovine
pituitary extract (50 mg per mL). When greater than 70% confluent,
primary cultured cells were trypsinized and seeded into either 24-
well culture plates at 5  105 cells per well or eight-well permanox
slides (Nalge Nunc International Corp., Rochester, New York), and
incubated for 12 h to allow for adhesion. The confluent cells were
then treated with APC (Xigris, Eli Lilly, Indianapolis, Indiana), PC
(Sigma, St Louis, Missouri), or TNF-a (Sigma) in the presence or
absence of ECPR blocking antibody RCR252, EPCR non-blocking
antibody RCR92 (gifts from Professor Fukudome, Department of
Immunology, Saga Medical School, Nabeshima, Saga, Japan), or
anti-PAR-1 antibody (Santa Cruz Biotechnology Inc., Santa Cruz,
California) in K-SFM without EGF for 24 h. Cells and culture super-
natants were collected for detection of mRNA and protein expres-
sion after treatment. The study was conducted according to the
Declaration of Helsinki Principles, and all participants gave their
written informed consent.
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay The colorimetric MTT assay was performed to quan-
titate the effect of different test agents on cell viability and to
standardize loading of gels. Briefly, 2  104 cells per well were
seeded in a 96-well microplate in a final volume of 200 mL, incu-
bated overnight, and treated with test agents for 24 h. Three hours
prior to the completion of the treatment, 10 mL of 5 mg per mL MTT
(Sigma) was added to the cells and cells were further incubated for
3 h. The MTT solution was then removed and replaced by 100 mL
dimethylsulfoxide, and the plates were shaken for 3 min. The
optical density was determined at a wavelength of 570 nm with
a reference wavelength of 630 nm.
RNA extraction and RT-PCR Total RNA was isolated from ker-
atinocytes using a TRI reagent (Sigma). Single-stranded cDNA
were synthesized from total RNA using AMV reverse transcriptase
and Oligo (dT)15 as primers (Promega Corp., Madison, Wisconsin).
RT products (2 mL) were amplified by PCR in a total volume of 20
mL to detect gene expression of EPCR (Galligan et al, 2001) and
PAR-1 (Buresi et al, 2001), as described previously. b-actin was
included as an internal standard (Xue et al, 2004). PCR products
were separated on a 2% agarose gel and imaged using the Infinity-
Capt Gel Documentation System (Vilber Lourmat, France). Relative
levels of mRNA were semi-quantified by comparing the intensity of
the band of interest with that of an internal standard (b-actin) using
image analysis.
Cell proliferation 5  103 cells per well were seeded into a 96-
well plate in 200 mL of growth medium in quadruplicate. Cells were
incubated for 72 h at 371C, and proliferation was measured using
the MTT assay as described above.
Western blot Keratinocytes were washed three times with PBS
and lysed with lysis buffer (0.15 M NaCl, 0.01 mM PMSF, 1% NP-
40, 0.02 M Tris, 6 M urea/H2O). Cell lysates were centrifuged at
10,000  g for 15 min, and protein concentration was determined
using the Bradford protein assays (Bio-Rad, Hercules, California).
Equal amounts of protein were separated by 10% sodium-do-
decyl-sulfate polyacrylamide-gel electrophoresis (SDS-PAGE) and
subjected to western blotting. The primary antibodies used in this
experiment were anti-EPCR antibody RCR252 (10 mg per mL); anti-
human PC (HC-2, 1:400 dilution, Sigma); anti-phosphorylated
forms of p38 MAPK; and ERK-2 and anti-PAR-1 antibody (1:500 or
1:1000 dilutions, Santa Cruz Biotechnology Inc.). Immunoreactivity
was detected using the ECL detection system (Amersham, Piscat-
away, New Jersey). Relative levels of protein were semi-quantified
using imaging analysis.
ELISA Total MMP-2 in cell culture supernatants were measured
by an MMP-2 ELISA kit (R&D Systems Inc., Minneapolis,
Minnesota) according to the manufacturer’s instructions.
Zymography MMP-2 activity in culture supernatants was analy-
zed by gelatin zymography, as previously described (Herron et al,
1996).
Immunohistochemical staining Cultured keratinocytes in eight-
well permanox slides were fixed with 4% paraformaldehyde.
Human foreskin was fixed with 10% PBS-buffered formalin, and
paraffin-embedded tissue was de-paraffinized and subjected to
immunohistochemistry. After quenching with 2% H2O2 in methanol
and equilibrating in PBS, samples were incubated with RCR252
(20 mg per mL) or negative control IgG (DAKO Corporation, Car-
pinteria, California) at 41C overnight. Samples were then processed
for staining using the DAKO LSABþSystems stain kit (DAKO Cor-
poration) and counterstained with hematoxylin and scotts blueing
solution.
Statistical analysis Significance was determined using one-way
ANOVA and the Student–Newman–Keul test. p values less than
0.05 were considered statistically significant.
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